Femasys (NASDAQ:FEMY) versus Beyond Air (NASDAQ:XAIR) Head-To-Head Analysis

Beyond Air (NASDAQ:XAIRGet Free Report) and Femasys (NASDAQ:FEMYGet Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Volatility & Risk

Beyond Air has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500. Comparatively, Femasys has a beta of -3.56, meaning that its share price is 456% less volatile than the S&P 500.

Earnings & Valuation

This table compares Beyond Air and Femasys’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Beyond Air $298,000.00 170.59 -$55.82 million ($2.06) -0.77
Femasys $1.09 million 13.10 -$11.39 million ($0.97) -0.98

Femasys has higher revenue and earnings than Beyond Air. Femasys is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

30.6% of Beyond Air shares are held by institutional investors. Comparatively, 8.3% of Femasys shares are held by institutional investors. 15.6% of Beyond Air shares are held by insiders. Comparatively, 16.4% of Femasys shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.


This table compares Beyond Air and Femasys’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Beyond Air N/A -152.87% -92.39%
Femasys -1,164.78% -100.01% -84.97%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Beyond Air and Femasys, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beyond Air 0 0 3 0 3.00
Femasys 0 0 3 0 3.00

Beyond Air currently has a consensus target price of $11.25, suggesting a potential upside of 607.55%. Femasys has a consensus target price of $9.00, suggesting a potential upside of 847.37%. Given Femasys’ higher possible upside, analysts plainly believe Femasys is more favorable than Beyond Air.


Femasys beats Beyond Air on 7 of the 12 factors compared between the two stocks.

About Beyond Air

(Get Free Report)

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

About Femasys

(Get Free Report)

Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.